Tags

Type your tag names separated by a space and hit enter

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Haematologica 2006; 91(5):663-6H

Abstract

Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions. The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI). Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT.

Authors+Show Affiliations

Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, Munich, Germany. martin.weisser@med.unimuenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article

Language

eng

PubMed ID

16627251

Citation

Weisser, Martin, et al. "A Comparison of Donor Lymphocyte Infusions or Imatinib Mesylate for Patients With Chronic Myelogenous Leukemia Who Have Relapsed After Allogeneic Stem Cell Transplantation." Haematologica, vol. 91, no. 5, 2006, pp. 663-6.
Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006;91(5):663-6.
Weisser, M., Tischer, J., Schnittger, S., Schoch, C., Ledderose, G., & Kolb, H. J. (2006). A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica, 91(5), pp. 663-6.
Weisser M, et al. A Comparison of Donor Lymphocyte Infusions or Imatinib Mesylate for Patients With Chronic Myelogenous Leukemia Who Have Relapsed After Allogeneic Stem Cell Transplantation. Haematologica. 2006;91(5):663-6. PubMed PMID: 16627251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. AU - Weisser,Martin, AU - Tischer,Johanna, AU - Schnittger,Susanne, AU - Schoch,Claudia, AU - Ledderose,Georg, AU - Kolb,Hans Jochem, Y1 - 2006/04/19/ PY - 2005/10/25/received PY - 2006/03/06/accepted PY - 2006/4/22/pubmed PY - 2006/8/25/medline PY - 2006/4/22/entrez SP - 663 EP - 6 JF - Haematologica JO - Haematologica VL - 91 IS - 5 N2 - Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions. The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI). Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/16627251/A_comparison_of_donor_lymphocyte_infusions_or_imatinib_mesylate_for_patients_with_chronic_myelogenous_leukemia_who_have_relapsed_after_allogeneic_stem_cell_transplantation_ L2 - http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=16627251 DB - PRIME DP - Unbound Medicine ER -